Holen Sie sich die Stockscreener-App
116.35
0.08%
0.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$116.26
Offen:
$115.71
24-Stunden-Volumen:
13.22M
Relative Volume:
1.49
Marktkapitalisierung:
$202.32B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.50B
KGV:
31.30
EPS:
3.717
Netto-Cashflow:
$7.40B
1W Leistung:
+3.69%
1M Leistung:
+7.46%
6M Leistung:
-11.49%
1J Leistung:
-14.37%
1-Tages-Spanne:
$115.49
$116.81
1-Wochen-Bereich:
$112.05
$116.81
52-Wochen-Spanne:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
116.35 | 202.16B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
387.46 | 147.74B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.66 | 124.39B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
76.85 | 112.40B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
86.47 | 49.85B | 6.07B | 1.06B | 799.60M | 1.8527 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Xponance Inc. Sells 31,276 Shares of Abbott Laboratories $ABT - MarketBeat
Primecap Management Co. CA Sells 65,100 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Erste Asset Management GmbH - MarketBeat
Abbott Laboratories (ABT) Announces $20 Billion Senior Notes Off - GuruFocus
Abbott Laboratories Announces $20 Billion Senior Notes Offering - Global Legal Chronicle
Abbott Laboratories Prices $20 Billion Senior Notes Offering - TipRanks
Abbott takes out M&A whopper amid drugs binge - GlobalCapital
Abbott Prices $20 Billion Multi-Tranche Notes to Fund Exact Sciences Deal - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Mixed Share Performance And Conflicting Fair Value Signals - Yahoo Finance
VivaVision Eyes Hong Kong Listing Before Cash Coffers Dry Up - Benzinga
Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now? - Nasdaq
Abbott’s US$20b Bond Bet Recasts Growth Story In Oncology Diagnostics - simplywall.st
US Bancorp DE Sells 37,572 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects - Seeking Alpha
Precision Medicine Market 2026–2031 Growth: 13%+ CAGR as AI Integration and Biomarker Advancements Drive Adoption, Reports Mordor Intelligence - GlobeNewswire Inc.
Pre-market: ABT.SW Abbott Laboratories (SIX) -12.00% to CHF88.00: watch CHF85.00 - Meyka
Abbott India: Quiet Rally In A Noisy MarketWhat US Investors Miss - AD HOC NEWS
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - AOL.com
Is Abbott Laboratories Stock Underperforming the Nasdaq? - Yahoo Finance
How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects - Yahoo Finance
Abbott Laboratories Secures Major Bond Issue to Fund Strategic Acquisition - AD HOC NEWS
Wrongful Death Case Tests Abbott’s FreeStyle Libre 3 Risk Oversight - simplywall.st
Abbott Laboratories Advances Major Acquisition Amid Market Scrutiny - AD HOC NEWS
Vestmark Advisory Solutions Inc. Cuts Stock Position in Abbott Laboratories $ABT - MarketBeat
Shanghai Henlius Biotech Expands Abbott License for HANSIZHUANG, Terminates KGBio Territories – Key Amendments and Market Impact 1234 - Minichart
Point of Care Diagnostics Market Competitive Landscape - GlobeNewswire
Point of Care Diagnostics Market Competitive Landscape Report 2025 Featuring Top 5 PlayersSysmex, Abbott Laboratories, Becton Dickinson and Co, Danaher, Quidel Diagnostics - Yahoo Finance
Exact Sciences shareholders give nod for acquisition by Abbott - Medical Buyer
Cardiac Marker Testing Market Is Going to Boom |• Abbott • Roche - openPR.com
Dakota Wealth Management Has $27.16 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness - Yahoo Finance
Abbott Laboratories Launches Landmark $20 Billion Bond Offering - AD HOC NEWS
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch - Meyka
Abbott (ABT) Ascends While Market Falls: Some Facts to Note - Nasdaq
Abbott Labs: A boring dividend machine that could quietly make you rich - MSN
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg.com
Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery - Insider Monkey
Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich - AOL.com
Key facts: Abbott Laboratories to raise $20 billion via bond sale; files for notes offering - TradingView
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves - simplywall.st
Abbott Laboratories (ABT) Investor Outlook: Exploring A Promising 18.87% Potential Upside - DirectorsTalk Interviews
Abbott lines up one of the year's biggest bond sales at $20B - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative
Abbott Laboratories (ABT) Plans $20B Bond Sale to Fund Exact Sci - GuruFocus
Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting - Yahoo Finance
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott kicks off bond sale for Exact Sciences deal - Modern Healthcare News
Abbott (ABT) Submits Automatic Mixed Securities Shelf Filing - GuruFocus
Abbott seeks $20 billion in US bond sale for Exact Sciences dealBloomberg News - marketscreener.com
Abbott files for eight-part notes offering, size not disclosedSEC filing - marketscreener.com
Abbott Labs Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition - marketscreener.com
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):